Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BVS vs VVOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BVS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

BVS Overall Winner 6-Pillar Tally: BVS 6 – 0 VVOS Matrix Metrics: BVS 9 – 1 VVOS

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BVS carries a Unified Composite Score of 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin), whereas VVOS carries 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin).

  • Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. VVOS 36.4/100 SELL) and 0.85β · 74% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BVS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BVS vs VVOS
BVS NASDAQ Head-to-Head Winner
Bioventus Inc. Class A Common Stock
Surgical & Medical Instruments & Apparatus
$9.88
-0.7% 1D
Market Cap $681.3M
TTM Revenue $586M
Forward P/E 11.1x
Beta / 30D Vol 0.85β · 74% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 64.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.4%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $11.75 · SMA50: $12.81
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13

6-Pillar Scorecard Institutional Category Breakdown (BVS 6 – 0 VVOS)

Columns: Metric · BVS · VVOS
1. Valuation Multiples BVS
Forward P/E 11.1x N/M
Trailing P/E 12.3x N/M
PEG Ratio 1.20x N/M
EV / Revenue 1.5x 0.1x
2. Growth & Scale BVS
Revenue Growth (YoY) +2.7% +34.9%
Earnings Growth (YoY) +69.7% +0.0%
TTM Revenue (USD) $586M $21M
Market Cap $681.3M $1.9M
3. Profitability & Quality BVS
Gross Margin 68.7% 61.9%
Operating Margin 10.1% -107.9%
Net Profit Margin 9.8% -121.8%
Return on Equity (ROE) 25.8% -8585.3%
4. Balance Sheet & Cash Flow BVS
Cash Generation (TTM) $85M -$21M EBITDA
Cash Flow Margin 14.5% -99.3% EBITDA Mgn
Net Cash / Leverage $199M Net Debt (0.96x D/E) -8585.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BVS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 448.1% (100th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BVS
OpEx & R&D Intensity 58.6% of Rev ($343M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BVS (9) vs VVOS (1)
Institutional Metric BVS VVOS Criterion Row Edge
Market Capitalization
Scale
$681.3M $1.9M Larger Scale BVS
Trailing P/E Ratio
Valuation
12.3x N/M Lower Multiple BVS
Forward P/E Ratio
Valuation
11.1x N/M Lower Multiple BVS
Revenue Growth (YoY)
Growth
+2.7% +34.9% Higher Growth VVOS
Operating Margin (TTM)
Profitability
10.1% -107.9% Higher Margin BVS
Net Profit Margin
Profitability
9.8% -121.8% Higher Margin BVS
Return on Equity (ROE)
Capital Efficiency
25.8% -8585.3% Higher ROE BVS
52-Week Range Position
Momentum
36% ($6–$16) 0% ($0–$3) Stronger Trend BVS
Beta / 30D Volatility
Risk Regime
0.85β · 74% Vol 1.70β · 111% Vol Lower Realized Risk BVS
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 36.4 / 100 (SELL) Higher Composite BVS
Trailing 12M Revenue (USD)
Operating Scale
$586M $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.7% 61.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.20x PEG · 1.5x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$85M ($199M Net Debt (0.96x D/E)) -$21M EBITDA (-8585.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BVS +24.94 pp
BVS: -34.31% · VVOS: -59.25%
3M Horizon BVS +50.96 pp
BVS: -29.53% · VVOS: -80.49%
6M Horizon BVS +97.62 pp
BVS: +6.47% · VVOS: -91.15%
1Y Horizon BVS +144.73 pp
BVS: +47.02% · VVOS: -97.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BVS Revenue VVOS Revenue BVS Op. Margin VVOS Op. Margin Margin Leader
FY2019 $340M $10M 9.2% -92.8% BVS
FY2020 $320M $10M 6.6% -92.1% BVS
FY2021 $430M $20M 2.8% -120.7% BVS
FY2022 $510M $20M -32.7% -156.2% BVS
FY2023 $510M $10M -16.0% -125.3% BVS
FY2024 $570M $20M -2.7% -74.3% BVS
FY2025 $570M $20M 9.5% -114.1% BVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BVS BREAKDOWN
76d in phase · OBV DISTRIBUTION
Current IV 448.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BVS Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $681.3M market capitalization and 10.1% operating margin.
OpEx & R&D Reinvestment 58.6% of Rev ($343M)
90D Engineering Disclosures 0 Published
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BVS vs VVOS Key Questions & Quantitative Answers

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BVS carries a Unified Composite Score of 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin), whereas VVOS carries 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin). Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. VVOS 36.4/100 SELL) and 0.85β · 74% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BVS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BVS leads the Growth & Scale pillar: BVS posts +2.7% YoY revenue growth and +69.7% YoY earnings growth on $586M TTM revenue (68.7% gross margin, 10.1% operating margin), compared with VVOS at +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), BVS cumulative revenue shifted +67.6% while VVOS shifted +100.0%. In operating R&D and SG&A reinvestment, BVS deploys 58.6% of Rev ($343M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VVOS.

BVS screens cheaper on headline valuation multiples. BVS trades at 11.1x Forward P/E, 12.3x Trailing P/E, 1.20x PEG, and 1.5x EV/Revenue (14.5% FCF margin), whereas VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BVS (25.8% ROE) versus VVOS (-8585.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BVS carries 448.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 74% Vol realized risk). By comparison, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.